Wolfram Samlowski, MD
Hematology & Oncology · Las Vegas, NVNPI 1396810834
Payments from drug & device makers
Across 347 payments — averaging $3188.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$840K
- Regeneron Healthcare Solutions, Inc.$93K
- E.r. Squibb & Sons, L.L.C.$64K
- Regeneron$40K
- Sanofi$26K
- Sun Pharmaceutical Industries Inc.$20K
- plus $25K from 31 others
Across 11 payments — averaging $1234.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$14K
What the payments were for
- Consulting fees$60,40126%
- Speaking & faculty fees$157,15767%
- Travel & lodging$10,0084%
- Food & beverage$7,5163%
- Education$3510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 21 | $839,689 |
| Regeneron Healthcare Solutions, Inc. | 57 | $92,563 |
| E.r. Squibb & Sons, L.L.C. | 63 | $63,868 |
| Regeneron | 11 | $39,940 |
| Sanofi | 19 | $25,702 |
| Sun Pharmaceutical Industries Inc. | 22 | $20,038 |
| Novartis | 34 | $18,961 |
| Eisai Inc. | 1 | $2,040 |
| Daiichi Sankyo Inc. | 55 | $741 |
| Bristol Myers Squibb | 7 | $689 |
| Exelixis Inc. | 7 | $260 |
| Medtronic | 1 | $164 |
| Intuitive Surgical | 3 | $157 |
| Immunocore Limited | 1 | $140 |
| Urogen Pharma, Inc. | 1 | $125 |
| Myovant Sciences Inc. | 1 | $125 |
| Tempus AI, Inc | 6 | $124 |
| Amgen | 2 | $121 |
| Olympus America Inc. | 1 | $117 |
| Lilly USA, LLC | 1 | $107 |
| Array Biopharma Inc | 5 | $94 |
| Astellas Pharma US Inc | 3 | $83 |
| Pfizer | 4 | $82 |
| GSK | 3 | $69 |
| Genentech USA, Inc. | 1 | $60 |
| AstraZeneca | 3 | $60 |
| Incyte Corporation | 1 | $50 |
| AbbVie | 2 | $49 |
| Beigene USA, Inc. | 2 | $48 |
| Mirati Therapeutics, Inc. | 2 | $31 |
| Iovance Biotherapeutics, Inc. | 1 | $21 |
| EMD Serono, Inc. | 1 | $21 |
| Seagen Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Springworks Therapeutics, Inc. | 1 | $16 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,106,422 in reported general payments places this provider in the 90th percentile of 82 hematology & oncology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 12 | $188,029 |
| JakafiRuxolitinib Phosphate | 17 | $177,978 |
| VenclextaVenetoclax | 27 | $146,268 |
| RydaptMidostaurin | 14 | $90,230 |
| EliquisApixaban | 29 | $23,110 |
| Bexarotene | 12 | $11,363 |
| XareltoRivaroxaban | 21 | $11,221 |
| Levothyroxine Sodium | 93 | $829 |
| Oxycodone Hcl | 25 | $706 |
| Prednisone | 91 | $679 |
| Hydrocortisone | 11 | $503 |
| Ondansetron OdtOndansetron | 42 | $437 |
| Gabapentin | 54 | $376 |
| Anastrozole | 21 | $248 |
| Triamcinolone Acetonide | 16 | $222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $48 | $188,02912 claims |
| Incyte CorporationJakafi | $50 | $177,97817 claims |
| AbbVieVenclexta | $49 | $146,26827 claims |
| NovartisRydapt | $18,961 | $90,23014 claims |
| PfizerEliquis | $82 | $23,11029 claims |
| Johnson & JohnsonXarelto | $18 | $11,22121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Las Vegas
- Edwin KingsleyLas Vegas$9.2M
- Nicholas VogelzangLas Vegas$8.3M
- Oscar GoodmanLas Vegas$6M
- Khawaja JahangirLas Vegas$2.5M
- Carolyn MulroneyLas Vegas$1.5M
- Anuradha ThummalaLas Vegas$736K
- Grzegorz ObaraLas Vegas$668K
- Aaron GoodmanLas Vegas$480K
- Vikas GuptaLas Vegas$300K
- Clark JeanLas Vegas$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.